How much protein do you need on a GLP-1 to protect muscle?

Dr. Linda's take

The question I hear is rarely "should I eat protein." It is sharper than that. It is "how much, exactly?" People want a number, because a number feels like something you can actually do something with. I understand the pull.

So let me be straight with you in the first paragraph: there is no official protein requirement written specifically for people taking these medications. What exists instead is a body of weight-loss and muscle research that predates them, and expert groups reasoning carefully from it. That is a real answer. It is just not a tidy one.

It also matters that protein is food, not a prescription. The ranges below are nutrition guidance, not a dose, and nobody is titrating your chicken breast. What I want to do here is show you where the numbers come from, how much confidence each one has earned, and what to carry into a conversation with a clinician who knows your history. This is general education, not advice about what you personally should eat.

Why does losing weight take muscle with it?

Fat is not the only tissue that responds to an energy deficit. When body weight comes down meaningfully, some lean mass, which includes skeletal muscle, comes down with it. This is not a quirk of any particular medication. It is what the body does when it is running on less.

The size of that effect is where it gets interesting. Across trials of tirzepatide and similar agents, the share of total weight lost that came from lean mass has ranged from about 15% to 50% of total weight loss. That is a wide range, and the width is itself the finding. It reflects genuine differences in who was studied, how body composition was measured, and how long people were followed. Anyone quoting you one confident figure is quoting one study.

The broader question of how to protect muscle overall is covered in our guide to preventing and reversing muscle loss during treatment. This article stays on the intake question: how much protein, and what the evidence actually says.

What did the trial body-composition data actually show?

The cleanest look comes from scanning people rather than weighing them. In the DXA body-composition substudy of SURMOUNT-1, 74% of the body weight reduction was fat mass and 26% was lean mass with tirzepatide, while it was 75% as fat mass and 25% as lean mass with placebo.

Read those two numbers next to each other, because the comparison is the entire point. Lean mass did fall. But the proportion of the loss that came from lean tissue was essentially identical to what happened in people not taking the medication. Losing some lean tissue is what losing weight does, in roughly the same ratio, regardless of what drove the loss.

A review of this literature made the same observation, noting that these proportions closely resemble those observed with diet-induced weight loss. The same review argued that the moderate lean tissue decline seen during treatment could be interpreted as a physiological component of body composition change rather than evidence of pathological sarcopenia.

That reframing is worth sitting with, because it changes what protein is for. Protein is not there to cancel out a drug effect. It is there because you are losing weight, and losing weight has always asked something of muscle. If you are navigating this in midlife, where lean mass is already drifting, we look at that specific overlap separately.

How much protein does the evidence actually support?

Here are the numbers that exist, with their pedigree attached.

An expert consensus statement on nutritional and lifestyle supportive care recommends that during the weight-loss phase, a protein intake of 1.2 to 1.5 g/kg actual body weight per day, or equivalent to 25% to 30% of energy on a 1600 kcal per day diet, is recommended. The same statement advises that during weight-loss maintenance, protein intake should be at least 0.8 g/kg actual body weight per day. It also explains that protein intake recommendations are often based on actual body weight because that basis is supported by extensive research, is less subjective than ideal or corrected body weight, and is easily understood and adjustable in clinical practice.

A separate review landed in nearly the same place, suggesting that a daily protein intake of 1.2 to 1.6 g/kg adjusted body weight should be considered in individuals initiating this therapy. And a randomised controlled trial protocol studying lean mass preservation during semaglutide and tirzepatide therapy set its own target at 1.6 g/kg per day, noting that protein intakes of 1.2 to 1.6 g/kg per day support lean mass preservation during energy restriction.

So three independent groups converge on roughly 1.2 to 1.6 g/kg per day. That convergence is meaningful. But now the honest part.

That upper anchor traces back to a meta-regression which found that protein supplementation beyond total protein intakes of 1.62 g/kg/day resulted in no further resistance-training-induced gains in fat-free mass. That analysis accepted only trials in humans who were healthy and not energy-restricted. In other words, the ceiling most often quoted to people losing weight was established in people who were not losing weight.

The consensus authors are candid about this too. They state that their statements were primarily derived from indirect evidence, including from existing evidence and established guidelines for nutrition therapy in bariatric medicine and relevant clinical experience, and that there is still a significant lack of direct evidence to guide clinical practice, making consensus-based recommendations necessary.

That is why I will not hand you one precise number and call it settled. The range is a reasonable inference from adjacent evidence, not a finding from a trial that asked this exact question in these exact patients.

One more thing the same consensus is clear about: a high protein intake alone does not increase muscle mass, and for preservation of lean body mass during weight loss, an exercise training program based on resistance training at moderate-to-high intensity is advised. Protein is permission for muscle to be kept. Loading it is what makes the case for keeping it.

Why does appetite suppression make this harder?

Because the medication is doing exactly what it was designed to do.

In a narrative review of dietary intake, participants on GLP-1 or GIP/GLP-1 RAs reduced caloric intake by 16% to 39% compared to those receiving placebo treatment. That is the mechanism working. It is also the practical problem, because protein targets do not shrink when your appetite does. A gram target that was unremarkable at your old intake can become most of your food at your new one.

The same review is direct about the evidence gap here, stating that there is a paucity of data on the adequacy of protein intake for maintenance of muscle mass and function. It also warns that low food intake and poor diet quality may contribute to loss of muscle in individuals taking GLP-1 or GIP/GLP-1 RAs, and that reduction in overall dietary intake while taking these medications may contribute to shortfalls in micronutrient intake, while lower protein intake may not be sufficient to sustain muscle health.

This is the part I would want you to take seriously. The risk is less that the medication is stripping muscle and more that a much smaller volume of food quietly stops carrying enough protein. That is a solvable problem, and it is a food-planning problem. For people who find whole-food protein hard to reach on a small appetite, we review supplement options separately.

What should you ask your clinician?

That last one is not a throwaway. The consensus statement advises that a registered dietitian should be involved in the assessment, delivery, and evaluation of care, and that treatment monitoring and follow-up should include regular assessment of dietary intake.

If you want a structured way into that conversation, Body Good Studio's quiz maps your symptoms to a starting point before you speak with a clinician.

Frequently asked questions

Is there an official protein requirement for people on these medications?

No. There is no protein requirement written specifically for this situation. The figures in circulation come from weight-loss, sarcopenia, and bariatric nutrition research, applied by expert groups through reasoning rather than through a trial that tested those targets in these patients. One consensus group states plainly that there is still a significant lack of direct evidence to guide clinical practice, making consensus-based recommendations necessary.

What protein range does the evidence support?

Roughly 1.2 to 1.6 g/kg per day during active weight loss, which is where several independent groups land. An expert consensus recommends 1.2 to 1.5 g/kg actual body weight per day during the weight-loss phase, a review suggests considering 1.2 to 1.6 g/kg adjusted body weight, and a trial protocol targeting lean mass preservation during semaglutide and tirzepatide therapy set 1.6 g/kg per day. These are nutrition ranges, not doses, and your own target is a clinical conversation.

How much of the weight lost is actually muscle?

In the SURMOUNT-1 body-composition substudy, 74% of the weight reduction was fat mass and 26% was lean mass with tirzepatide, versus 75% fat and 25% lean with placebo. Across the wider literature, the lean share has ranged from about 15% to 50% of total weight loss, which is why no single number is trustworthy on its own.

Does more protein always mean more muscle?

No. The consensus statement is explicit that a high protein intake alone does not increase muscle mass, and advises resistance training at moderate-to-high intensity for preservation of lean body mass during weight loss. Separately, a meta-regression found no further resistance-training-induced gains in fat-free mass beyond total protein intakes of 1.62 g/kg/day, so more is not indefinitely better.

Why is protein harder to eat on this treatment?

Because intake drops substantially. In a review of dietary intake studies, participants reduced caloric intake by 16% to 39% compared with placebo. The target stays the same while the plate gets smaller, which means protein has to occupy a larger share of a much smaller amount of food.

References

1. Alawadhi AA, Alroudhan D, Alsaeed DJ, et al. (2026). LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ Open, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC13110620/ (Accessed 2026-07-16).
2. Look M, Dunn JP, Kushner RF, et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11965027/ (Accessed 2026-07-16).
3. Rossi G, Bucciarelli L, Mananguite CL, Giovarelli M, Fiorina P (2025). Muscle loss and GLP-1R agonists use. Acta Diabetologica, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC12957034/ (Accessed 2026-07-16).
4. Sievenpiper JL, Ard J, Blüher M, Chen W, Dixon JB, Fitch A, et al. (2025). Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: An expert consensus statement using a modified Delphi approach. Obesity Pillars, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC12768930/ (Accessed 2026-07-16).
5. Morton RW, Murphy KT, McKellar SR, et al. (2018). A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC5867436/ (Accessed 2026-07-16).
6. Christensen S, Robinson K, Thomas S, Williams DR (2024). Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obesity Pillars, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11340591/ (Accessed 2026-07-16).